Infectious Diseases
An 18‑Month VLA15 Booster Elicits Robust Anti‑OspA Responses and Shows Favorable Tolerability Across Ages
An 18‑month booster of the VLA15 Lyme vaccine candidate produced strong anamnestic anti‑OspA IgG responses exceeding primary‑series levels in children, adolescents, and adults, with a tolerability profile similar to primary doses.
